Literature DB >> 20338825

The determination and application of fixed-dose analgesic combinations for treating multimodal pain.

Robert B Raffa1, Joseph V Pergolizzi, Ronald J Tallarida.   

Abstract

UNLABELLED: When the pathophysiology of a medical condition is multimodal, ie, related to multiple physiological causes or mediated by multiple pathways, the optimal strategy can be to use a drug or a combination of drugs that contribute multiple mechanisms to the therapeutic endpoint. In such situations, a rational multimodal approach can also result in the fewest adverse effects. We discuss the quantitative analysis of multimodal action using the treatment of pain as a practical example and give examples of its application to some widely used analgesic drugs. PERSPECTIVE: This article reviews the medical relevance of the quantitative evaluation of drug combinations, using pain and combinations of analgesics as specific examples. Such measure can help clinicians who seek to maximize therapeutic effect while simultaneously minimizing adverse effects. Copyright (c) 2010 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20338825      PMCID: PMC2920146          DOI: 10.1016/j.jpain.2009.12.010

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  54 in total

1.  The interaction index: a measure of drug synergism.

Authors:  Ronald J Tallarida
Journal:  Pain       Date:  2002-07       Impact factor: 6.961

2.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

Review 3.  Interactions between drugs and occupied receptors.

Authors:  Ronald J Tallarida
Journal:  Pharmacol Ther       Date:  2006-09-07       Impact factor: 12.310

Review 4.  Combination opioid analgesics.

Authors:  Howard S Smith
Journal:  Pain Physician       Date:  2008 Mar-Apr       Impact factor: 4.965

5.  Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function.

Authors:  M Kömhoff; H J Grone; T Klein; H W Seyberth; R M Nüsing
Journal:  Am J Physiol       Date:  1997-04

6.  Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol.

Authors:  R B Raffa; E Friderichs; W Reimann; R P Shank; E E Codd; J L Vaught; H I Jacoby; N Selve
Journal:  J Pharmacol Exp Ther       Date:  1993-10       Impact factor: 4.030

7.  Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats.

Authors:  Jason M Lashbrook; Michael H Ossipov; John C Hunter; Robert B Raffa; Ronald J Tallarida; Frank Porreca
Journal:  Pain       Date:  1999-07       Impact factor: 6.961

8.  Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate.

Authors:  E J Simon; J M Hiller; I Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-07       Impact factor: 11.205

9.  Change in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia.

Authors:  Ariel Berger; Ellen Dukes; Bill McCarberg; Marty Liss; Gerry Oster
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

Review 10.  Combination strategies for pain management.

Authors:  Robert B Raffa; Rachel Clark-Vetri; Ronald J Tallarida; Albert I Wertheimer
Journal:  Expert Opin Pharmacother       Date:  2003-10       Impact factor: 3.889

View more
  15 in total

1.  Preemptive Oral Ketorolac with Local Tramadol Versus Oral Ketorolac in Third Molar Surgery: A Comparative Clinical Trial.

Authors:  Heena Mazhar; Ratna Samudrawar; Prashant Tamgadge; Rashmi Wasekar; Rahul Vinay Chandra Tiwari; Heena Tiwari
Journal:  J Maxillofac Oral Surg       Date:  2020-06-26

2.  Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence.

Authors:  Xiaoyan Lin; Amey S Dhopeshwarkar; Megan Huibregtse; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2017-11-30       Impact factor: 4.436

3.  Tapentadol in the management of chronic low back pain: a novel approach to a complex condition?

Authors:  Joseph Pergolizzi; Eli Alon; Ralf Baron; Cesare Bonezzi; Jan Dobrogowski; Rafael Gálvez; Troels Jensen; Hans-Georg Kress; Marco Ae Marcus; Bart Morlion; Serge Perrot; Rolf-Detlef Treede
Journal:  J Pain Res       Date:  2011-07-21       Impact factor: 3.133

4.  Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects.

Authors:  Sebastián Videla; Mounia Lahjou; Anna Vaqué; Mariano Sust; Mercedes Encabo; Lluis Soler; Artur Sans; Eric Sicard; Neus Gascón; Gregorio Encina; Carlos Plata-Salamán
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

5.  Co-crystals as a new approach to multimodal analgesia and the treatment of pain.

Authors:  Carmen Almansa; Christopher S Frampton; José Miguel Vela; Steve Whitelock; Carlos R Plata-Salamán
Journal:  J Pain Res       Date:  2019-09-04       Impact factor: 3.133

6.  Expert Consensus on Clinical Use of an Orally Administered Dexketoprofen Plus Tramadol Fixed-Dose Combination in Moderate-To-Severe Acute Pain: A Delphi Study.

Authors:  Giustino Varrassi; Stefano Coaccioli; Josè De-Andrés; Magdi Hanna; Giorgos Macheras; Antonio Montero; Serge Perrot; Vincenzo Piras; Carmelo Scarpignato
Journal:  Adv Ther       Date:  2019-09-18       Impact factor: 3.845

7.  Wherefore Gabapentinoids?: Was There Rush Too Soon to Judgment?

Authors:  Evan D Kharasch; James C Eisenach
Journal:  Anesthesiology       Date:  2016-01       Impact factor: 8.986

8.  Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial.

Authors:  Sebastián Videla; Mounia Lahjou; Anna Vaqué; Mariano Sust; Marisol Escriche; Lluis Soler; Artur Sans; Eric Sicard; Neus Gascón; Gregorio Encina; Carlos Plata-Salamán
Journal:  Br J Clin Pharmacol       Date:  2017-10-12       Impact factor: 4.335

9.  Durapain in symptomatic treatment of severe acute pain: a post-marketing, prospective, multicenter, observational study - PRIME study.

Authors:  Kshitij Shah; Omvijay B Chaudhari; Palash Gupta; R Hom Chaudhuri; Ranjan Kamilya; Shreedhar S Kulkarni; S Subbaiah; Zubair H Sorathia; Gauri Billa
Journal:  J Pain Res       Date:  2017-05-25       Impact factor: 3.133

10.  Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac or Ketorolac.

Authors:  Héctor Isaac Rocha-González; María Elena Sánchez-Mendoza; Leticia Cruz-Antonio; Francisco Javier Flores-Murrieta; Xochilt Itzel Cornelio-Huerta; Jesús Arrieta
Journal:  Molecules       Date:  2020-11-03       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.